drugset / Trial / NCT07585747
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the efficacy and safety of orelabrutinib, tafasitamab, and lenalidomide in the first-line treatment of patients with follicular lymphoma.
Timeline
- Start
- 2026-04-15
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Orelabrutinib | Small molecule | 150 mg | Oral |
| Subject | Tafasitamab | Monoclonal antibody | 12 mg/kg | Intravenous |